ALKS - Alkermes plc
| Previous Close | 18.45 |
| Open | 19.25 |
| Bid | 19.21 x 3000 |
| Ask | 19.23 x 800 |
| Day's Range | 18.47 - 20.66 |
| 52 Week Range | 17.11 - 42.69 |
| Volume | 2,534,617 |
| Avg. Volume | 1,217,758 |
| Market Cap | 3.018B |
| Beta (3Y Monthly) | 1.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.17 |
| Earnings Date | Oct 23, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.58 |
- Zacks
Alkermes (ALKS) Reports Q3 Loss, Tops Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of 80.00% and 1.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring
-- Third Quarter Revenues of $255.2 Million , Primarily Driven by Approximately 20% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.34 and Non-GAAP ...
- Zacks
Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
- PR Newswire
Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
DUBLIN, Oct. 21, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced that it has entered into a clinical research collaboration with Fred Hutchinson Cancer Research Center (Fred Hutch) for ALKS 4230, Alkermes' immuno-oncology drug candidate. ALKS 4230 is a novel, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity interleukin-2 (IL-2) receptor complex. The planned phase 2 multi-site trial, ION-01, is designed to estimate the response rate to ALKS 4230 in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced or recurrent head and neck squamous cell cancer who did not achieve complete remission with an anti-PD-(L)1 antibody treatment.
- PR Newswire
Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results
DUBLIN , Oct. 16, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, October 23, 2019 , to discuss the ...
- Zacks
Biogen Strengthens MS & SMA Portfolio as Competition Lurks
Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.
- PR Newswire
Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress
-- Findings From Patient Surveys Underscore Need for New Antipsychotic Treatments With Reduced Side Effects -- DUBLIN , Oct. 7, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation ...
- PR Newswire
Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference
DUBLIN , Sept. 26, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, ...
- Zacks
Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy
Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex
- Simply Wall St.
Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- GuruFocus.com
Alkermes Plc (ALKS) Director and CEO, Alkermes plc Richard F Pops Sold $2.3 million of Shares
Director and CEO, Alkermes plc of Alkermes Plc (30-Year Financial, Insider Trades) Richard F Pops (insider trades) sold 100,000 shares of ALKS on 09/12/2019 at an average price of $22.68 a share. Continue reading...
- PR Newswire
Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.
DUBLIN, Sept. 13, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.D. and Frank Anders (Andy) Wilson, to the company's Board of Directors. The company also announced the retirement of Floyd Bloom, M.D., a pioneer in the field of neuroscience who contributed immensely to the legacy of innovation and scientific excellence that remains core to Alkermes' mission today. Dr. Gaynor, who currently serves as the President of Research & Development at Neon Therapeutics, brings 18 years of experience in oncology-focused industrial drug development in addition to a distinguished career in academic medicine.
- Zacks
Why Is Alkermes (ALKS) Down 3.9% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
An Intrinsic Calculation For Alkermes plc (NASDAQ:ALKS) Suggests It's 49% Undervalued
In this article we are going to estimate the intrinsic value of Alkermes plc (NASDAQ:ALKS) by taking the foreast...
- Zacks
Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.
- Zacks
Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.
- PR Newswire
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
DUBLIN and CAMBRIDGE, Mass., July 30, 2019 /PRNewswire/ -- Alkermes plc (ALKS) and Biogen Inc. (BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis (RRMS), compared to TECFIDERA® (dimethyl fumarate). Diroximel fumarate was statistically superior to dimethyl fumarate on the study's pre-specified primary endpoint, with patients treated with diroximel fumarate self-reporting significantly fewer days of key gastrointestinal (GI) symptoms with intensity scores ≥2 on the Individual Gastrointestinal Symptom and Impact Scale (IGISIS), as compared to dimethyl fumarate (p = 0.0003).
- PR Newswire
Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute
Under the agreement, the parties agreed to request termination of the IPR and Alkermes granted Amneal the non-exclusive right to market a generic formulation of VIVITROL in the U.S. beginning sometime in 2028 or earlier under certain circumstances. Additional terms of the agreement are confidential.
- Thomson Reuters StreetEvents
Edited Transcript of ALKS earnings conference call or presentation 25-Jul-19 12:00pm GMT
Q2 2019 Alkermes Plc Earnings Call
- Zacks
Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2
Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019.
- Benzinga
The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics ...
Motley FoolAlkermes PLC (ALKS) Q2 2019 Earnings Call Transcript
ALKS earnings call for the period ending June 30, 2019.
